降钙素基因相关肽(CGRP)是目前已知最强的血管舒张剂,具有强大的舒张脑血管和神经细胞保护作用,已开始试用于临床高血压和脑卒中的治疗。但CGRP与其他调节肽一样,由于在体内极易降解,又不能透过血脑屏障,因此作为药物在临床应用,受到一定限制。 人工生物膜—磷脂脂质体可以运载药物到达特异的靶组织,并延缓药物的代谢。本工作选用特异性趋向脑组织的脂质体,包囊CGRP,观察CGRP在大鼠体内的分布,以探讨其临床应用的可能性。 Calcitonin gene-related peptide (CGRP) is currently the strongest known vasodilator, has a strong protective effect of diastolic cerebral blood vessels and nerve cells, has begun trial for the treatment of clinical hypertension and stroke. However, CGRP, like other regulatory peptides, has some limitations in its clinical application as a drug because it can easily degrade in the body and can not penetrate the blood-brain barrier. Artificial biofilm - phospholipid liposomes can carry drugs to a specific target tissue, and delay the metabolism of drugs. The purpose of this study was to investigate the distribution of CGRP in rats and to explore the possibility of its clinical application.